Adel Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • IPO Registration

  • Employees
  • 20

Employees

  • Latest Deal Type
  • IPO
  • (Announced)

  • Investors
  • 17

Adel General Information

Description

Developer of therapeutic antibodies designed to treat neurodegenerative diseases. The company utilizes a proprietary research and development platform to create humanized monoclonal antibodies that selectively target acetylated tau proteins, enabling pharmaceutical companies to inhibit toxic protein aggregation while preserving normal microtubule functions.

Contact Information

Website
www.adelpharm.com
Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Corporate Office
  • 3F & 5F, Hans Building, 90 Pungseong-ro
  • Gangdong-gu
  • Seoul
  • South Korea
+82
Primary Industry
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • 3F & 5F, Hans Building, 90 Pungseong-ro
  • Gangdong-gu
  • Seoul
  • South Korea
+82

Adel Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adel Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. IPO 18-Jun-2026 Announced Generating Revenue/Not Profitable
6. Later Stage VC 09-Apr-2026 Completed Clinical Trials - Phase 1
5. Later Stage VC (Series B) 03-Sep-2024 Completed Clinical Trials - General
4. Early Stage VC (Series B) 01-Jan-2020 Completed Clinical Trials - General
3. Early Stage VC (Series A) 01-Jan-2018 Completed Clinical Trials - General
2. Accelerator/Incubator 01-Jan-2018 Completed Clinical Trials - General
1. Seed Round 01-Jan-2018 Completed Clinical Trials - General
To view Adel’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Adel Patents

  • 29

    Total Documents Applications and Grants

  • Total Patents Families

  • 13

    Granted

  • 11

    Pending

  • Expiring in next 12 mo

Adel Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026024136-A1 Anti-β2-microglobulin antibody and uses thereof Pending 26-Jul-2024
WO-2025258951-A1 Anti-apolipoprotein e4 (apoe4) antibodies and uses thereof Pending 10-Jun-2024
AU-2023389615-A1 Fusion comprising anti-tau antibody and peptide and use thereof Pending 08-Dec-2022
EP-4631975-A1 Fusion comprising anti-tau antibody and peptide and use thereof Pending 08-Dec-2022
US-20260201024-A1 Fusion comprising anti-tau antibody and peptide and use thereof Pending 08-Dec-2022 C07K16/18
To view Adel’s complete patent history, request access »

Adel Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Adel Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
DS Asset Management Asset Manager Minority
Korea Investment Partners Venture Capital Minority
Loftyrock Investment Venture Capital Minority
Mirae Asset Securities Investment Bank Minority
Samsung Securities Corporation Minority
You’re viewing 5 of 17 investors. Get the full list »

Ready to get started?

Request a free trial

Adel FAQs

  • When was Adel founded?

    Adel was founded in 2016.

  • Where is Adel headquartered?

    Adel is headquartered in Seoul, South Korea.

  • What is the size of Adel?

    Adel has 20 total employees.

  • What industry is Adel in?

    Adel’s primary industry is Drug Discovery.

  • Is Adel a private or public company?

    Adel is a Private company.

  • What is Adel’s current revenue?

    The current revenue for Adel is .

  • How much funding has Adel raised over time?

    Adel has raised $12.7M.

  • Who are Adel’s investors?

    DS Asset Management, Korea Investment Partners, Loftyrock Investment, Mirae Asset Securities, and Samsung Securities are 5 of 17 investors who have invested in Adel.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process